| 摘要: |
| c-Met为酪氨酸激酶受体的一种,肝细胞生长因子(HGF)为其天然配体。c-Met的激活主要有HGF配体依赖型和非HGF配体依赖型两种形式。许多恶性肿瘤包括肺癌中存在c-Met的多种活化机制,c-Met的异常激活亦与肺癌的发生发展及恶性生物学行为关系密切。本文就c-Met的活化与非小细胞肺癌及小细胞肺癌的关系及其靶向药物在肺癌中的研究进展作一综述。 |
| 关键词: 原癌基因蛋白质c-Met 肺肿瘤 靶向治疗 |
| DOI：10.3724/SP.J.1008.2013.00557 |
| 投稿时间：2013-03-17修订日期：2013-04-19 |
| 基金项目: |
|
| Abnormal activation of c-Met in lung cancer and research progress of the targeted drugs: a review |
| CAO Xu1,YANG Yang2,SUN Ye-qi1,CHEN Gang1* |
(1. Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China
2. Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China
*Corresponding author.) |
| Abstract: |
| c-Met is a receptor tyrosine kinase (RTK) with hepatocyte growth factor (HGF) as its natural ligand. c-Met may be activated in a ligand-dependent manner by binding HGF or in a ligand-independent manner. Diverse activation mechanisms of c-Met exist in many malignant tumors, including lung cancer. Moreover, the abnormal activation of c-Met has a close relationship with the occurrence, development and malignant biological behavior of lung cancer. This paper focused on the different activation mechanisms of c-Met in non-small cell lung cancer and small cell lung cancer and also reviewed the research progress of c-Met targeted drugs in lung cancer. |
| Key words: proto-oncogene proteins c-Met lung neoplasms targeted therapy |
